AstraZeneca PLC Director/PDMR Shareholding (0331G)
July 21 2021 - 10:56AM
UK Regulatory
TIDMAZN
RNS Number : 0331G
AstraZeneca PLC
21 July 2021
21 July 2021 15:50 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 21 July 2021,
Marc Dunoyer, Chief Financial Officer, received 21,243 Ordinary
Shares of $0.25 each in the Company (Ordinary Shares). The Ordinary
Shares were issued to Mr Dunoyer on completion of the Company's
acquisition of Alexion Pharmaceuticals, Inc. (Alexion) as part
consideration for the 20,000 Alexion shares held by Mr Dunoyer at
the time of completion.
In accordance with the Agreement and Plan of Merger entered into
by the Company on 12 December 2020, as consideration for each
Alexion share held on completion of the acquisition, being 21 July
2021, Alexion shareholders received $60 in cash and, at their
election, either 2.1243 AstraZeneca American Depositary Shares
(each representing one half of an Ordinary Share) or the Ordinary
Share equivalent.
PDMR Nature of the transaction Quantity Estimated
of Ordinary valuation
Shares received of price
per Ordinary
Share
Marc Dunoyer Ordinary Shares issued in 21,243 US$115.08
consideration for the acquisition
of Alexion Pharmaceuticals,
Inc.
----------------------------------- ----------------- --------------
The attached notification, made in accordance with the
requirements of the EU and UK Market Abuse Regulations, gives
further detail.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Marc Dunoyer
-------------------------- -------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- -------------------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- -------------------------------------------------
b) Nature of the transaction Ordinary Shares issued in consideration
for the acquisition of Alexion Pharmaceuticals,
Inc.
-------------------------- -------------------------------------------------
c) Price(s) and volume(s) Price(s)* Volume(s)
US$115.08 21,243
----------
*non-cash consideration: price is
an estimated valuation
-------------------------- -------------------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- -------------------------------------------------
e) Date of the transaction 21 July 2021
-------------------------- -------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology, Rare Diseases and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries, and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUAVSRAUUBUAR
(END) Dow Jones Newswires
July 21, 2021 10:56 ET (14:56 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
